Citi analyst Yigal Nochomovitz lowered the firm’s price target on Candel Therapeutics (CADL) to $24 from $25 and keeps a Buy rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Advances Cancer Therapies with Strong Q3
- Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year
- Candel Therapeutics announces it will deliver three presentations at SITC
- Candel initiated with an Overweight at Stephens on differentiated pipeline
- Candel Therapeutics initiated with an Overweight at Stephens